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ABSTRACT
Background: In 1999, Saskatchewan Health authorized pharmacists to
initiate exception drug status (EdS) requests, also known as prior autho-
rization (Pa). Before 1999, only those licensed to prescribe medications
were authorized to initiate EdS requests. a pharmacist who submits an
EdS request must obtain a patient diagnosis from the physician or agent
of the physician; a diagnosis presented by the patient is insufficient.
oBjEctIvE: to obtain pharmacists’ opinions about the benefits of the Pa
program of the Saskatchewan drug Plan and to identify factors associated
with pharmacist-initiated EdS requests.
MEtHodS: a census survey of community pharmacy managers was con-
ducted via a self-administered postal questionnaire in the province of
Saskatchewan, canada, in the fall of 2004. the survey questionnaire was
addressed to pharmacy managers, some of whom may have delegated the
response to a staff pharmacist. Pharmacy managers or their delegates
were asked to respond on behalf of all pharmacists in their pharmacies.
rESuLtS: a response rate of 82.6% was achieved (275/333). a majority
of respondents agreed that the province’s Pa program (EdS) benefited
patients (87.3%) and the Saskatchewan drug Plan (82.5%), whereas only
33.4% of respondents agreed that the EdS program benefited pharma-
cists. Pharmacists’ ability to obtain the requisite information (87.6%) and
to contact the prescribing physician (87.3%), as well as patient-centered
concerns such as the patient’s ability to pay for the prescription (85.1%),
were the most important factors. the time required by the pharma-
cist to initiate the request was not important relative to other factors.
community pharmacies reported receipt of an average of 36.4 prescrip-
tions for restricted and nonformulary drugs per week, of which 22 were
submitted for Pa coverage, 17 by the pharmacy and 5 by the pharmacy at
the request of the physician.
concLuSIonS: the results of this study indicate that community pharma-
cists in Saskatchewan acknowledge that the EdS process is beneficial for
their patients. However, pharmacists are burdened by an administrative
process in which necessary information, particularly the patient diagnosis,
is not readily available.
kEYWordS: Pharmacist, Policy, Prior authorization, Step therapy, drug plan
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What is already known about this subject
What this study adds
Medicare in Canada is a federal program that has evolvedover nearly 40 years to provide Canadians access to med-ically necessary physician and hospital services, includ-
ing drugs administered in hospitals. However, each provincial and
territorial government independently developed and continues to
develop programs to provide drug coverage for some or all of its
residents in the community or in nonhospital facilities. The federal
government has also developed and continues to develop drug pro-
grams for select groups, including veterans and First Nations and
Inuit peoples. However, more than half of all prescriptions are paid
through private insurance or directly by individuals or patients.1,2
In 2005, Canada had 7,778 community pharmacies comprising
chain and banner pharmacies (58.6%), independent pharmacies
(21.4%), and pharmacies in food and mass merchandisers (20.0%).3
In 2005 in Saskatchewan, public funds paid for 48% of the $554
per capita spent on prescription drugs, whereas Canada as a
whole spent $640 per capita on prescription drugs, with 46% of
the expenditure paid for with public funds.4 The average retail
price for a prescription in 2005 was $45.66, which included
dispensing and professional fees.3 As in other countries, the final
cost to the patient varied considerably depending on the markup
and dispensing fee charged.
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• Prior-approval or prior-authorization (PA) programs reduce
direct drug cost by imposing criteria for coverage such as prior
use of first-line therapy (i.e., step therapy) or a patient diagnosis
with a higher probability of a favorable response to the drug.
• As prescription drug use increases, drug and managed care
plan administrators are developing and implementing cost-
containment mechanisms to encourage the use of lower-cost
drugs while promoting cost-effective use of more expensive
and generally newer drug therapies.
• This is the first study of the opinions of pharmacists with regard
to the administrative procedures involved in a PA program.
• Pharmacy managers and pharmacists are not opposed to
PA programs but are dissatisfied with the administrative
burden of the requirement to obtain the patient diagnosis
from the physician.
CONTEMPORARY SUBJECT
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Over the years, increasing reliance on drug therapy and a
tendency to abandon older drug therapies for newer, more expen-
sive agents have caused drug utilization rates and expenditures
for prescription drugs to grow substantially.1,5,6 Drug plans have
attempted to control these rising costs in a variety of ways,
including limiting coverage to certain cohorts of the population
(i.e., low-income families), increasing copayments, or introducing
deductibles. The result has been an ongoing shifting of costs to
patients and private insurers.7,8
In 1973, the Saskatchewan provincial government imple-
mented a comprehensive drug plan via Saskatchewan Health’s
Drug Plan and Extended Benefits (Drug Plan) Branch. All costs,
with the exception of a small copayment, were publicly funded.7,9
Today, Saskatchewan residents are still covered by the provincial
drug plan, but most beneficiaries must meet an annual, income-
based deductible (3.4% of household income) before receiving any
financial support from the government.9 Since July 2007, seniors
(all Saskatchewan residents aged 65 years and older) pay no more
than Can $15 per prescription (1-month supply) for drugs listed
on the province’s formulary.10
Utilization trends in Saskatchewan provide an interesting
picture of drug expenditures in the province. In 1995-1996,
633,333 active beneficiaries in Saskatchewan received 5,798,090
prescriptions for a total prescription cost of Can $157,194,207
(Can $248 per beneficiary), and the Drug Plan paid Can $59,492,033
(37.8%) of the total cost.9 Ten years later, in 2005-2006,
the number of active beneficiaries had increased by only
0.8% to 638,637, while the number of prescriptions increased
62% to 9,364,871 and total prescription costs increased by
239% to Can $375,304,926 (Can $588 per beneficiary); the
Saskatchewan Drug Plan paid Can $181,288,493 (48.3%) of
the total prescription cost, an increase of 305%.9
Therefore, while the number of active beneficiaries remained
virtually unchanged, the number of prescriptions per active bene-
ficiary, average cost per prescription, and per prescription propor-
tion paid by the Saskatchewan Drug Plan increased dramatically.
Managed care interventions that have been implemented, such as
prior authorization (PA) in the late 1970s and therapeutic maxi-
mum allowable cost, which began with proton pump inhibitors in
July 2004, are attempts by the Saskatchewan Drug Plan to control
escalating costs and thereby ensure its long-term viability.
Even with restrictive policies and cost shifting, drug utilization
rates continue to rise and, with them, the cost of providing drug
coverage.11 Both public and private drug plans have expanded
various management strategies such as PA in an attempt to stem
rising drug expenditures while maintaining access to effective drug
therapies. PA limits the use of selected drugs by requiring advance
approval for reimbursement of certain drugs when less costly alter-
natives are available.12 However, some aspects of these strategies can
become sources of contention between payers, patients, and health
care providers because they may be perceived as limiting access to
needed drugs by requiring administrative approval for coverage.
Additional administrative tasks are associated with these programs
that health care professionals are expected to assume.13
In Saskatchewan, PA is known as the Exception Drug Status
(EDS) program.14 For the patient to receive provincial government
coverage for restricted formulary drugs, EDS approval must first be
obtained—a process that must be initiated by an authorized health
care professional (physician, dentist, optometrist, nurse practitio-
ner, or pharmacist). Some private drug plans have the same or
similar requirements for drugs in the Saskatchewan EDS program.
A few examples of EDS program drugs and coverage criteria include
azithromycin permitted for patients intolerant to erythromycin
and/or other antibiotics, insulin lispro permitted for treatment of
patients using insulin pumps or difficult-to-control diabetes, and
pioglitazone hydrochloride (HCl) or rosiglitazone maleate permit-
ted for treatment of patients who previously received prescriptions
for metformin or sulfonylureas and are not adequately controlled on
or are intolerant to metformin or sulfonylureas.15
When submitting an EDS request, the authorized health care
professional can phone, mail, or fax the request to Saskatchewan
Health; however, only the patient and prescribing physician
receive confirmation letters. The pharmacist is notified when he
or she accesses the patient profile via the Drug Plan’s database.
Information required to submit an EDS request includes the
(1) patient name, (2) patient health services number, (3) diagno-
sis relevant to use of drug, and (4) prescriber name and phone
number.15 The information required to submit an EDS request for
a nonapproved drug includes (1) the disease or problem treated,
(2) the list of previous therapies and responses, (3) other non-EDS
therapies tried and why they are not appropriate for the patient,
(4) clinical evidence to support the therapy being requested, and
(5) outcomes to assess effectiveness of the requested therapy.15
(Figure for EDS request form.16)
In July 2006, the Drug Plan implemented online adjudication
for 2 drugs (pioglitazone HCl and rosiglitazone maleate) through an
electronic step-therapy program. EDS claims for these 2 drugs can
be submitted and adjudicated directly through the online claims
transaction system.15 For these 2 drugs, the online transaction pro-
cessing system checks the patient’s drug profile and if the first-line
drugs (metformin or sulfonylureas) appear in the system, the cover-
age and approval letter is automatically generated for the patient.15
Health care professionals as a whole are not compensated by the
Saskatchewan Drug Plan for EDS requests. However, the Medical
Services Branch (not the Saskatchewan Drug Plan and Extended
Benefits Branch that administers the EDS program), compensates
physicians Can $4 for information requests from health care
professionals, including pharmacists, for a diagnosis from the
physician to submit an EDS request. (written communication,
G. Bradley, January 2005). Therefore, if the physician writes on
the prescription “apply for EDS” but does not provide the required
diagnosis on the written prescription, when the pharmacist con-
tacts the physician to obtain the patient’s diagnosis, the physician
may claim a Can $4 fee for that information request.
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FIGURE Saskatchewan Health Exception Drug Status Request Form16
Saskatchewan
Health
Drug Plan & Extended Benefits Branch 3475 Albert Street
Regina SK SAS 6X6
306-787-3420 Phone
306-798-1089 Fax
EXECEPTION DRUG STATUS REQUEST FORM







Health Services Number: _____________________________
Date of Birth: _________ / _________ / _________
DAY/MONTH/YEAR
Sex: ❏ Male ❏ Female
dRUG INfoRMATIoN (See Appendix A for specific criteria)
Drug(s) Requested: ____________________________________________________________
(include name, dosage form, and strength)
Diagnosis (be specific): ____________________________________________________________
(must be obtained from physician or physician’s agent obtained by: ❏ Fax ❏ Phone ❏ Written on RX
only - cannot be obtained from the patient)
Alternative agents tried (be specific): ____________________________________________________________
Drug allergies (be specific): ____________________________________________________________
Drug intolerances (be specfic): ____________________________________________________________
Other information relavent to this request: ____________________________________________________________
for Pharmacy Use only for Physician Use only
Pharmacist Name: ________________________________
Pharmacy Name: _________________________________
Pharmacy Phone Number: __________________________
Pharmacy Fax Number: ____________________________
Prescribing Physician: _____________________________
Physician M.S.P. Number:___________________________
Locum for Dr. (if applicable):_________________________
Physician Name: _________________________________
Physician M.S.P. Number: __________________________





dRUG PlAN USE oNly
fAx REqUEST To dRUG PlAN (306) 798-1089
fax Back Information: HIRf INfo:
❏ 30 ❏ P1
❏ Pc ❏ P2
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Before 1999, only those practitioners licensed to prescribe
in the province were able to initiate EDS requests. In 1999,
Saskatchewan Health expanded the program to allow licensed
pharmacists to apply for EDS on behalf of their patients.
Allowing pharmacists to initiate these requests was seen as a way
to improve access to prescription medication and assist patients
in securing all available sources of funding for their prescription
medications.14 However, the EDS program requires the phar-
macist to obtain the patient’s diagnosis from the physician or
physician’s agent in order to submit an EDS request.15
Since 1999, when licensed pharmacists in Saskatchewan were
allowed to initiate EDS requests, research has not been con-
ducted on how the policy affects community pharmacy practice.
As noted in previous studies on PA or step-therapy programs,17-20
often the drug costs and savings are evaluated while the perspec-
tive of the providers (e.g., pharmacists) are not addressed. This
paper reports on the experiences and opinions of community
pharmacy managers, or their delegates, and their pharmacies
with regard to Saskatchewan Health’s EDS program and its
effect on community pharmacy. Ethics approval was applied for
and received from the University of Saskatchewan’s Behavioural
Research Ethics Board before this survey was conducted.
Methods
Study Sample and Design
A census survey of community pharmacy managers in
Saskatchewan was conducted in the fall of 2004. Pharmacy
managers were chosen over individual pharmacists to reduce the
potential of having 2 or more pharmacists’ perspectives represent-
ed from the same pharmacy. In September 2004, we received an
up-to-date list of all 346 community pharmacies in the province
from the Saskatchewan College of Pharmacists, the regulatory
body for pharmacists in Saskatchewan. In identifying distinct
community practices, we reduced the number to 333 as a result
of pharmacy closure (1) and of pharmacies operating as satellites
in remote communities that did not have a pharmacy manager
and/or pharmacist specifically for the satellite location (12).
Following the Tailored Design Method for the conduct of sur-
veys, we sent a prior notice letter in October 2004 to community
pharmacy managers who were licensed pharmacists.21 In the
letter, prospective survey respondents were asked to complete
the questionnaire when it arrived or to designate a member of
their staff whom they thought was most qualified to answer. This
presurvey letter was followed 1 week later by the questionnaire,
which included a cover letter and prestamped return envelope.
A reminder postcard to nonresponders was sent 2 weeks later.
A final mailing was sent 2 weeks after the reminder postcard to
nonrespondents and included another copy of the questionnaire,
a cover letter, and a prestamped return envelope. The study col-
lection period closed 4 weeks after the final mailing.
Once the study period concluded, we performed a nonrespon-
dent survey. A one-time questionnaire and cover letter, along
with a prestamped return envelope, were sent to nonrespondents
in an attempt to estimate potential biases in the sample.
Survey Instrument
Drawing on a review of the relevant literature,6,22-44 we con-
structed the questionnaire to address a series of topics relating
to PA and the EDS program in Saskatchewan. These topic areas
included potential stakeholder benefits from a PA program, the
volume of EDS requests received by the pharmacy, factors influ-
encing the decision to initiate a request, and the appropriateness
of procedures used to submit a request. Information was also
gathered with regard to the area, location, and type of pharmacy;
the number of pharmacists and pharmacy technicians in the
respondent’s pharmacy; the proximity of the prescribing physi-
cians; prescription volume; and hours the dispensary was open.
Demographics were also collected on respondents’ gender, age,
position, and years in their current position.
After the questionnaire was developed, content and format
were evaluated using a pretest involving 5 community pharmacy
managers. In the pretest, managers were asked to provide feed-
back on the design of the questionnaire, its relevance, and the
flow of individual questions and between sections. Comments
were also obtained from Saskatchewan Drug Plan representatives
and an expert in questionnaire design from the Department of
Management and Marketing, College of Commerce, University
of Saskatchewan.
The final instrument contained 5 pages of questions with
an average of 8 questions on each page (a copy of the instru-
ment is available from the corresponding author). Items were
measured primarily with 5-point and 7-point Likert-type scales.
Respondents were also asked to complete a demographics page,
and space was provided for additional comments, which are
reported elsewhere.46
Data Analysis
Descriptive statistics were calculated for all items. Comparative
analysis was carried out using the Mann-Whitney U test and
Kruskal-Wallis One-Way Analysis of Variance. Nonparametric tests
were selected over parametric tests because of the primarily ordinal
nature of the data. For post hoc analysis, the Bonferroni test was
used to identify statistically significant differences between respon-
dents when factors were compared. All statistical analyses were
conducted using SPSS 13.0 for Windows (Chicago, IL).
Results
Study Population
A total of 279 questionnaires were returned. After data collec-
tion concluded, 4 additional questionnaires were received but
were not included in the analysis. Of the eligible questionnaires
received, 275 were properly completed, for a final response
rate of 82.6% (275/333). Of the 50 nonrespondent question-
naires that were mailed after the study period, 15 were returned
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(30%). There were no statistically significant differences between
respondents of the original survey and respondents of the non-
respondent survey on any common measures, including gender,
respondents’ position, proximity to prescriber, community size,
average number of prescriptions filled per week, and hours the
pharmacy was open (data not presented).
Of the 273 respondents reporting their gender, nearly two
thirds were male (64.2%). Almost half (49.1%) identified them-
selves as the manager, and more than one third of respondents
identified themselves as the owner (36.4%). The reported average
prescription volume per week (745, Table 1) is lower than the
national average of 833.5 The average number of pharmacists
(2.8) and pharmacy technicians (2.4) per location were also
below the national average of 3.5 and 4.3, respectively.5
An average of 36 restricted/nonformulary prescriptions
were received per week which represented 5% of the reported
prescription volume (Table 1). Compared with 1999, when
pharmacies did not submit any EDS requests, we found that
respondents reported that their pharmacies submitted 79%
of all requests, with 29% of these EDS requests submitted
by the pharmacy at the request of the prescribing physi-
cian. Therefore, community pharmacies submit an average
of about 17 EDS requests per week out of the 59% of 22
of the restricted and nonformulary prescriptions received
by the pharmacy and submitted by either the pharmacy or
physician. Circumstances such as the patient not meeting the
EDS exception criteria (e.g., not having tried previous drug
therapies required for approval or not having the tests done
[such as culture and sensitivity for some antibiotics]) makes
submission of some requests unnecessary.
Stakeholders and the EDS Program
A majority of respondents (63%) agreed or strongly agreed
that the EDS program benefited patients by expanding the
number of prescription medications covered by the provin-
cial drug plan (Table 2). A majority (64%) also agreed or
strongly agreed that the provincial drug plan benefited from
the EDS program by allowing costly medications to be avail-
able in a more controlled manner.
Fewer respondents agreed or strongly agreed that the EDS
program benefited the health care system (39%) by promoting
more appropriate utilization of drugs, while 37% of commu-
nity pharmacy managers agreed or strongly agreed that the EDS
program benefited physicians by providing them with more
drug therapy choices for their patients. Only 15% of respon-
dents agreed or strongly agreed that the EDS program benefited
pharmacists by providing them with an opportunity to be more
actively involved in securing the most appropriate drug therapy
for their patients.
Factors Associated With a Pharmacist-Initiated EDS Request
In assessing the importance of factors that might influence
whether a pharmacist initiated an EDS request on behalf of the
patient, 74% of respondents indicated the ability of the patient
to pay for the prescription was an important or very important
factor (Table 3). Other factors seen as important or very impor-
tant in initiating an EDS request included the ability to obtain
all the information needed to make the request (77%) and the
pharmacist’s ability to contact the prescribing physician (70%).
Respondents who were in the same location (co-located in the
same building) as the prescribing physician were less likely to
consider proximity as a factor compared with those who were
removed geographically (χ2 = 18.41; P < 0.01, data not shown in
tables). The time required to submit an EDS request was seen as
the least important factor, with only 39% indicating this factor
as important or very important.
Experience With EDS Requests
Seventy-nine percent of respondents agreed or strongly
agreed that pharmacists in their pharmacy believe that
initiating an EDS request is an important service for their
patients, and 75% agreed or strongly agreed that they had
adequate information on the administrative nature of the EDS
program (Table 4).
With regard to the 1999 policy change allowing pharmacists
to initiate EDS requests, 71% agreed or strongly agreed that the
change in policy had been beneficial to patient care. However,
most (96%) agreed that the change had significantly increased
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Pharmacy Characteristics – Saskatchewan (n=275*) Mean [SD]
Number of pharmacists 2.8 [1.6]
Full-time equivalents 2.4 [1.4]
Number of pharmacy technicians 1.4 [1.7]
Full-time equivalents 1.0 [1.3]
Prescriptions per week 745 [504]
Pharmacy hours per week 62.0 [22.6]
Exception Drug Status Volume Per Week
Number of restricted/non-formulary prescriptions
received – mean [SD]
36.4 [48.4]
Number (%) submitted for coverage† 22 (59.1%)
Number (%) initiated by the pharmacy 17 (78.8%)
Number (%) initiated by pharmacy at physician’s request 5 (29.4%)
*48 (17.5%) of these 275 pharmacies were located in the same building with pre-
scribers of EDS drugs.
† Circumstances such as the patient not meeting the EDS exception criteria (e.g.,
not having tried previous drug therapies required for approval or not having the
tests done such as culture and sensitivity for some antibiotics) makes submission of
some requests unnecessary.
TABLE 1 Pharmacy Characteristics and
Exception Drug Status (EDS) Volumes
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the administrative workload of pharmacists, but pharmacies that
filled 0 to 250 prescriptions per week (15.9%) were less likely to
agree with this statement than were those filling more than 500
(58.0%) prescriptions per week (χ2 = 12.87; P < 0.01, data not
shown in tables).
Discussion
As prescription drug use and expenditures continue to
increase,11 various interventions such as PA are implemented to
manage the use of pharmaceuticals—targeting drugs for which
there are less costly alternatives available.12 The principal
stakeholders in PA programs are patients, pharmacists, physi-
cians, drug plans, and administrators.28,34,36,39,41 Traditionally,
physicians have been the health care professionals that apply
for PA coverage for a patient, but some drug plans such as the
Saskatchewan Drug Plan have authorized pharmacists to also
initiate PA requests.
Other researchers have established the financial benefits
of PA or step-therapy programs by identifying a reduction in
direct drug costs.18-20 Through the examination of one aspect
of the humanistic-service outcomes, the present study expands
our understanding of PA programs. Specifically, we examined
some of the factors associated with the uptake of a policy
designed to allow pharmacists to apply for PA on behalf of
their patients and the perceptions of community pharmacists
associated with this policy.
While we did not measure the proportion of pharmacy staff
time required for EDS submissions, the administrative burden
is not small since preparing and submitting EDS requests
requires more time than simply filling the prescription.
Furthermore, pharmacists are not compensated financially for
the service. It is not surprising that most respondents indi-
cated that the current EDS policy was beneficial to patients
and precribers but viewed the policy as an additional burden
for pharmacists.
Given the additional workload demands that the EDS pro-
gram places on pharmacists, it was not unexpected that the
respondents believed that pharmacists benefited the least from
the EDS program. However, it was somewhat surprising that
pharmacists reported that the time required to provide the ser-
vice was the least important factor when deciding to initiate an
EDS request. Factors such as the ability to obtain the required
information and the ability to contact the prescriber were of
greater concern. This suggests a need to improve communication
and the role definition for both the pharmacist and the physi-
cian. Effective communication and collaboration between physi-
cians and pharmacists will likely improve humanistic-service
outcomes for patients, including reduction in the time delays in
obtaining medications.18
Respondents in the same location as prescribing physicians
were less likely to be concerned with their ability to contact the
physician. Co-locations and greater opportunity for face-to-face
interaction allows the pharmacist(s) to establish good working
relationships with prescribers. Good working relationships, in
turn, would be expected to support greater accessibility when
initiating an EDS request.
The ability of the patient to pay was also a key factor in
pharmacist decisions to submit requests for EDS coverage. If a
patient is unable to pay the cost share for the medication, even if
approved via EDS, it is not productive for the pharmacist to apply
for EDS coverage.
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Although it appears that respondents do not necessarily
mind the time required to submit an EDS request, they are
concerned about their ability to obtain the information neces-
sary for initiating an EDS request. The fact that pharmacists
are not likely to have the information required for an EDS
request is troubling. The idea behind authorizing pharma-
cists to apply for EDS on behalf of patients was to increase
timely access to prescription drugs for patients. However,
when the pharmacist does not have the necessary informa-
tion to make that request in a timely manner, the process may
actually be lengthened.36
An evolving partial solution may be found in the Saskatchewan
Pharmaceutical Information Program (PIP). PIP is designed to link
community physicians, pharmacies, and hospitals, providing con-
fidential shared access to patient medication histories.46 However,
while PIP may help alleviate some of the current barriers to phar-
macist review of the complete medication history for a patient, it
does not provide the pharmacist with access to other medical infor-
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207 (75.3) 44 (16.1) 13 (4.7) 7 (2.5) 3 (1.1)
Initiating EDS is an important
service to patients
218 (79.3) 35 (12.7) 12 (4.4) 4 (1.5) 6 (2.2)
Policy change is beneficial to
patient health care
195 (70.9) 43 (15.6) 19 (6.9) 6 (2.2) 12 (4.4)
Program contributes
significantly to workload
238 (86.5) 25 (9.1) 7 (2.5) 2 (0.7) 3 (1.1)
EDS=exception drug status.
TABLE 3 Factors Associated With the Pharmacy Initiating an EDS
Factors Determining Whether the
















Ability to obtain all the
necessary information
211 (76.7) 30 (10.9) 10 (3.6) 6 (2.2) 18 (6.5)
Ability to track the status
of the EDS request
141 (51.3) 54 (19.6) 38 (13.8) 6 (2.2) 36 (13.1)
Ability to contact the
prescribing physician
193 (70.2) 47 (17.1) 14 (5.1) 2 (0.7) 19 (6.9)
Time needed to submit an EDS request 107 (38.9) 43 (15.6) 25 (9.1) 21 (7.6) 79 (28.7)
Familiarity with the EDS
administrative processes
123 (44.7) 37 (13.5) 54 (19.7) 10 (3.6) 50 (18.2)
Patient Costs
Patient will eventually exceed
the deductible
163 (59.3) 60 (21.8) 21 (7.6) 12 (4.4) 19 (6.9)
Patient has exceeded the
drug plan deductible
181 (65.8) 49 (17.8) 17 (6.2) 9 (3.3) 19 (6.9)
Ability of the patient to pay
for the prescription
202 (73.5) 32 (11.6) 11 (4.0) 12 (4.4) 18 (6.5)
EDS=exception drug status
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mation, such as the patient diagnosis, that is presently required to
initiate an EDS request.
In July 2006, the Saskatchewan Drug Plan implemented
2 changes to help streamline the EDS application process. First,
indefinite approval was permitted for 116 drugs or 442 EDS
drug information numbers (DINs), analogous to National Drug
Code (NDC) numbers in the United States. Second, online
adjudication was implemented for 2 drugs, pioglitazone HCl
and rosiglitazone maleate. EDS claims for these agents can be
submitted and adjudicated directly through the online claims
transactional processing system, which employs a “smart edit”
to search for evidence of prior use of first-line therapy or prior
use of the target drug that would have been associated with
an EDS approval.15 While this is a positive step in addressing
some of the issues around the administrative workload inherent
in PA programs, the online adjudication system currently only
includes 2 drugs.
Funding is clearly needed to institute measures that expedite
and streamline the manner in which pharmacists apply for EDS,
such as the move to online adjudication (smart edit). In addition,
consideration must be given to paying pharmacists an appro-
priate fee for the service they provide. Financial compensation
is important because it gives tangible recognition of the
pharmacist’s professional role in delivering appropriate drug
therapy while also providing an incentive for pharmacists
and pharmacies to provide a service that clearly benefits
patients in improved access to care and physicians in reduced
administrative workload.
Limitations
First, this is a preliminary study of pharmacist perceptions
that did not involve collecting information that might be used
to improve processes such as the average time required of
pharmacy staff per EDS submission and the proportion of total
pharmacy time and payroll consumed by the EDS process.
Second, the results obtained from the survey pertain only to the
province of Saskatchewan, Canada, and may not be applicable
to other jurisdictions. Third, since this survey was addressed to
community pharmacy managers, the respondents tended to be
older and were often the owners of the pharmacies. Therefore,
the opinions recorded in this survey may not represent practic-
ing pharmacists in general.
Conclusions
Pharmacists responding to the survey viewed the EDS program as
being beneficial to patients but were concerned with the admin-
istrative burden. Concerns with the EDS program focus on the
administrative nature of the program, including the inefficient
manner in which pharmacists are required to apply for EDS
due to lack of access to required patient information, including
diagnosis and complete prescription drug history. To maintain
pharmacists’ support for this managed care intervention, it will
be necessary to reduce the administrative workload by provid-
ing access to required information and implementing smart edits
that scan pharmacy claims history for evidence of prior use of
first-line drug therapy. Further research is needed to capture the
perceptions and experiences of all stakeholders of the EDS pro-
gram, including pharmacists, physicians, patients, and drug plan
personnel, to help assess humanistic-service outcomes of this
managed care intervention.
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